Objective. Supraventricular tachyarrhythmias (SVT) complicate postoperative management after coronary bypass surgery in about 30% of all patients. Though a prophylactic treatment both with/~-adrenergic blocking agents and the calcium antagonist diltiazem has been used for the prevention of post-operative SVT, no study yet has performed a prospective comparison of the efficacy of these therapies. Methods. To investigate the prophylactic effect of either a calcium antagonist (diltiazem, 0_1 mg/kg per h i_v.) or a/~-adrenergic blocking agent (propranolol, 10 mg every 6 h postoperatively), we randomized prospectively 103 consecutive patients into three groups, the third one serving as a control group. Anti-arrhythmic medication was started with the procedure and was continued until the 3rd postoperative day. Results. Preoperative conditions were the same for the three groups concerning age, extent of coronary heart disease, ventricular function and heartrelated medication. There were no differences in intraoperative parameters or postoperative enzyme patterns_ Diltiazem was ineffective in preventing SVT, the incidence being exactly the same as in the control group (35%). Propranolol reduced the occurrence of SVT significantly (7%, P < 0.05). Furthermore, patients treated with diltiazem needed positive inotropic support more often in the first hours after surgery than patients of the control group (30% vs 5%, P<0.01).
Introduction
In the early postoperative period after coronary artery bypass graft operations (CABG) supraventricular tachyarrhythmias (SVT) occur in about 30% of all patients [1, 2, 12-16, 19, 20, 24, 27] . Though SVT are commonly considered a relatively benign complication, they are associated with an increased incidence of postoperative stroke (3.3% vs 1.4%) and increased length of hospitalization [6] . Several risk factors for the occurrence of SVT have been described. Though the quality of intraoperative myocardial protection certainly contributes to the preservation of functional integrity, its influence on the occurrence of SVT remains questionable [2, 20] . Many studies have addressed the question of anti-arrhythmic drug prophylaxis, mostly investigating digitalis or /6-adrenergic receptor blocking agents. Whereas the administration of digitalis has yielded conflicting results [14, 17, 19, 28] , low-dose ]~-adrenergic receptor blockade, namely with propranolol, has been shown to be beneficial for the prevention of postoperative SVT [1, 12-16, 19, 20, 24, 27] . Some more recent studies recommend diltiazem, a calcium antagonist [7, 8, 22] . However, no study yet has involved a prospective comparison of the efficacy of prophylactic propranolol treatment to that of diltiazem.
Methods and materials
One hundred three consecutive patients were randomized prospectively into three groups before CABG. Patients with unstable angina (NYHA IV), bradycardia (<50 bpm), chronic obstructive lung disease, a preoperative ejection fraction less than 0.4, a preoperative history of SVT and additional surgical procedures were excluded from the study. Routine medication was terminated the evening before the operation.
Patients assigned to group 1 received diltiazem continuously (0.1 mg/kg per h i.v.) from the beginning of anesthesia until 72 h after the end of aortic cross-clamping. During the same period, patients assigned to group 2 received 10 mg propranolol every 6 h postoperatively and patients assigned to group 3 (control) received no antiarrhythmic agent. Patients with postoperative low cardiac output or hypotension who required significant doses of catecholamines, i_e. any adrenaline or dopamine/dobutamine more than 10 mg/h or noradrenaline more than 0.1 mg/h, for more than 6 h postoperatively, were withdrawn from the study.
All surgical procedures were performed in moderate hypothermia. A William Harvey HF-5700 membrane oxygenator and a twostage venous return cannula were used. Cardiac arrest was achieved using Buckberg blood cardioplegia via the aortic root. Anesthesia was standardized in all patients and consisted of body weight-related doses of methohexital and alfentanil.
Hemodynamic parameters (heart rate, blood pressure, central venous pressure) were assessed continuously during the first 24 h postoperatively and hourly thereafter. Continuous three-channel electrocardiographic (ECG) monitoring was performed during the investigated period by an experienced physician. In addition, twelve lead ECG recordings were performed shortly after operation and 24, 48 and 72 h after the end of aortic cross-clamping. Blood pressure values were calculated as a mean over a 24-h period for each day following surgery. In all patients, serum levels of creatine kinase (CK), MB-isoenzyme (CK-MB), GOT, GPT and LDH were measured immediately after operation and 6, 24, 48 and 72 h after the end of aortic cross-clamping_ Myocardial infarction was defined as persistent ST-segment of 2 mm and more in at least one ECG channel, a new Q-wave development, or postoperative elevation of the CK-MB level exceeding 32 U/16 h, or 18 U/124 h, after the end of aortic crossclamping [2, 10] .
For analysis of variance and significance of means ANOVA tables, Scheffe's post-hoc test and the unpaired t-test were applied. For significance of incidence, the chi-square test was used. All parameters were computed using SuperANOVA software. The study protocol was approved by the Warzburg Ethics Committee, all patients included in the study gave their written and informed consent. Table 1 shows preoperative and intraoperative clinical and surgical data. There were no significant differences between the three groups concerning age, prevalence of hypertension, history of myocardial infarction, NYHA classification or extent of coronary artery disease. Only stenosis of the Ramus circumflexus was more frequent in the control group (control vs diltiazem P < 0.05, control vs propranolol P<0.05). Medication with nitrates, beta blockers, calcium channel blockers and digitalis was distributed evenly over the total number of patients treated in each group preoperatively and the number of patients that developed SVT. Nor were there any differences in surgical data, such as aortic cross-clamping time, total bypass time, number of distal anastomoses, and number of internal mammary artery grafts.
Results
We did not find any significant differences between the three groups in the hemodynamic parameters monitored in the postoperative period. Mean values of heart rate and blood pressure and the number of patients requiring pacemaker stimulation did not differ for each 24-h period. No differences in cardiac enzyme levels were detected_ Neither in peak values of CK, CK-MB, GOT, GPT and LDH nor in any single value taken during a period of 72 h after the end of aortic cross-clamping.
Ten out of 33 patients (30%) treated with diltiazem received significant doses of catecholamines during the first 6 h after surgery, 9 of those (27%) had to be withdrawn from the study after the 6th h. In the second group, treated with propranolol, 6 out of 33 patients (18%) needed catecholamines in the early phase, 5 of those (15%) having to be discontinued thereafter. In the control group only 2 out of 37 patients (5%) received catecholamines, withdrawal due to hypotension after the 6th h was not possible since there was no double-blind study design. This difference is significant for diltiazem vs control (P<0.01) as shown in Table 2 . In one patient treated with diltiazem the study had to be discontinued because of ventricular arrhythmias and the consecutive application of other anti-arrhythmic drugs. On the other hand, one patient developed bradycardia in the group treated with propranolol. The incidence of myocardial infarction was low, as only one patient suffered a perioperative myocardial infarction in the control group and one in the propranolol group.
Of the remaining 23 patients of the diltiazem group, 8 (35%) developed SVT. This was not different to the control group's 13 out of 37 (35%). Only 2 out of 27 patients treated with propranolol developed SVT (7%). This difference reached statistical significance, see Table 2 . The average time of onset of SVT was identical in all three groups, around the 50th h. The follow-up to the 7th postoperative day showed that 2 out of 15 patients in the diltiazem group and one patient in the control group developed SVT, whereas no patient treated with propranolol did.
Discussion
Supraventricular tachyarrhythmias (SVT) complicate the early postoperative period after coronary artery bypass . Though SVT are commonly considered relatively benign, as 95% of the patients are back to a sinus rhythm within 7 days after surgery [2], they may reduce cardiac output, prolonging hospitalization in the intensive care unit and increasing the incidence of stroke [6] . The predisposing factors for this complication are still under discussion and include old age [2, 6, 7, 29], pre-existing cardiac damage [29] , the type of venous line [26] , longer bypass time [2, 6, 14, 17], biochemical changes associated with the use of cardioplegic solutions and sudden withdrawal of fi-adrenergic receptor blocking drugs [1, 21] . Insufficient protection of the atrium seems to be the main reason for the development of SVT after cardiac surgery. Investigations showing that bypass time, a degree of hypothermia and type of venous cannulization are responsible for SVT, support this hypothesis.
Smith found that the atrial myocardium was cooled less effectively than the ventricular myocardium and rewarmed rapidly during the period of cardioplegic arrest [25] . Therefore cold crystalloid cardioplegia does not adequately arrest the atria. Thus intraoperative damage of the atrial myocytes leads to a delay of the conduction in the atrioventricular node [26] with shortening of the effective refractory period, facilitating re-entry and ectopic autonomy [5] . Electrolytic imbalances caused by cardioplegic solutions seem to play a minor role in the development of SVT, since we could not demonstrate an effect of three different cardioplegic solutions on the occurrence of SVT in a prospective and randomized study [2] .
A depletion of ATP stores and an increased cytoplasmatic Ca ++ concentration are found in myocardial cell ischemia [3, 23] . Ca-channel blockers decrease the inward flow and, therefore, intracellular Ca ++ accumulation. Thus, during ischemia, Ca-channel blockers protect mitochondrial ATP production [for a review see 4]. Moreover, prophylactic diltiazem treatment has been shown to reduce postoperative SVT [8, 9, 22] , perioperative ischemic episodes [ l 8], as well as postoperative cardiac enzyme levels [8, 22] . Since catecholamines have positive chronotropic and inotropic actions, fl-adrenergic antagonists slow the heart rate and decrease myocardial oxygen consumption. Several trials have shown that administration of fl-adrenergic receptor blockers during the early phases of acute myocardial infarction may decrease mortality by about 10% [11] . In coronary artery disease fl-adrenergic receptor blockers are a common treatment and their withdrawal is supposed to be a risk factor for the development of postoperative SVT [1, 21] . Hence both fl-adrenergic receptor blockers and Ca-channel blockers should be beneficial for the prevention of postoperative SVT and may offer perioperative myocardial protection.
In contrast to other investigators we could not prove any effect of diltiazem on the occurrence of SVT. Its incidence with 35%, is identical to that of the control group. E1-Sadek described a reduction of SVT by diltiazem [9] , but in his study the incidence was as high as 80% on the 1st postoperative day in the control group and 60% and 50% on the 3rd and 5th days, respectively. This is clearly at variance with most other papers concerning this subject, as they present figures of between 15 and 40% [i, 2, 12-16, 19, 20, 24, 27] . The SVT were diagnosed by continuous Holter monitoring. Patients were operated either in fibillation or in cardioplegic arrest. Hence his patient groups were heterogenous, a comparison is statistically not correct and may result in misleading findings. Seitelberger described a reduction of atrial fibrillation from 18% to 5% by continuous diltiazem infusion during the first 24 h after operation [22] . Both Seitelberger and E1-Sadek used Holter monitoring for detection of SVT, whereas in our study a continuous three-channel ECG was performed. Thus, it is possible that short episodes of SVT may not have been recorded. According to our estimation, the clinical relevance of SVT consisting only of a few beats, which may have been missed, is limited. Donegani described a significant reduction of SVT after CABG [8] , but he administered 0.5 to 3.0 gg/kg per min, which was up to twice our dosis.
We conclude that diltiazem does not reduce clinically relevant SVT in the dosis applied in this study. A higher dosis does not seem appropriate because we had to withdraw 27% of all patients treated with diltiazem from the study due to hypotension or necessary positive inotropic support with catecholamines. E1-Sadek, Donegani and Seitelberger deny possible negative hemodynamic effects like prolonged hypotension or an increased need for catecholamine application for diltiazem [8, 9, 22] . Only Seitelberger presents figures for catecholamine application. This and the number of patients withdrawn because of hypotension remain unclear in most studies [8, 9] . Different types of anesthetic drugs could be a possible explanation for the relatively large number of patients which had to be withdrawn because ofhypotension. Our patients received a barbiturate (methohexital), possessing a calcium antagonizing activity of its own, thus diltiazem may have reduced blood pressure to a greater extent than described by other investigators. Since we did not have a double-blind design, withdrawal was not possible in the control group. Therefore the incidence of hypotension in the control group was not tested for significance against the propranolol and diltiazem groups.
Diltiazem failed to reduce cardiac enzyme levels in this study. Donegani found a reduction of cardiac enzyme release, but he did not give mean values [8] . Seitelberger applied the same dosis of diltiazem and described a reduction of mean values of cardiac enzyme levels [22] . Although our study designs were similar, e.g. the same dosis of diltiazem was applied, we could not prove this effect. Probst found a reduction of myocardial ischemic episodes by an automatic ST-slope analysis in patients who underwent CABG and had perioperative diltiazem application during and shortly after operation [18] . His experimental design allowed closer perioperative mapping of ischemic episodes than our study, but he did not correlate his findings with cardiac enzyme levels. We conclude that, if diltiazem does reduce ischemic episodes, this does not lead to reduced cardiac enzyme levels.
The value of propranolol in preventing SVT has been demonstrated in several studies. Whereas an untreated control group showed a mean incidence of SVT of 29%, lowdose propranolol reduced SVT to a mean incidence of 9% (in 10 studies). Our results, with an incidence of 7%, support these findings. Cox described than in 5% of all patients undergoing any type of major surgery, including cardiac surgery, postoperative atrial fibrillation is unavoidable because these patients are extremely vulnerable to the development of postoperative atrial fibrillation due to preexisting myocardial conditions [5] . Therefore an incidence of 7% of postoperative SVT in the propranolol group seems to describe a prophylaxis close to the optimum. Furthermore, patients treated with propranolol needed less positive inotropic support than patients treated with diltiazem.
We believe that low-dose propranolol is an effective prophylactic treatment for the prevention of SVT after CABG in patients with normal or slightly depressed left ventricular function. Diltiazem does not offer protection against postoperative SVT in the dosis applied and does not reduce cardiac enzyme levels.
